Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

February 9, 2022

Treatments for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) are being developed to address refractory cases, in other words, those that no longer respond to current therapies. In this study presented at the American Society of Hematology Annual Meeting and Exhibition (ASH 2021), the results of early (phase
The short answer is that it is certainly beginning to look that way for a lucky few. This month celebrated the 10th CAR-T anniversary of Doug Olson, who remains cancer-free with persistent CAR-T cells that still play WHACK-A-MOLE should any cancerous CLL cells dare to reappear.
These are indeed uncharted waters. There is the obvious risk of ventilators and death with everyone we encounter a possible unwitting carrier of the virus. For those of us who are both older and immunocompromised, there is a psychological element to all this that is underestimated.